Adjunctive use of platelet glycoprotein IIb/IIIa inhibitors for carotid angioplasty and stent placement: time to say good bye?
Qureshi
Adnan I
AI
Department of Neurology and Neurosciences, University of Medicine and Dentistry at New Jersey, Newark 07103, USA. aiqureshi@hotmail.com
D000077284:Abciximab; D017130:Angioplasty; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D016893:Carotid Stenosis / Q000601:surgery*; D000077542:Eptifibatide; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D010455:Peptides / Q000009:adverse effects*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011183:Postoperative Complications / Q000139:chemically induced / Q000453:epidemiology*; D015607:Stents; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000009:adverse effects* / Q000031:analogs & derivatives
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D006493:Heparin; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab